Supporting information:

Table S1: amino acid sequences of peptides that mediate the oligomerization of STIL IDR as found in the peptide array screening

Residues	peptide sequence
367-381	FSKASKNF <mark>SIKRS</mark> SQ
376-390	IKRS <mark>SQKLS</mark> SGKMPI
382-396	KLS <mark>SGKMP</mark> IHDHDSG
406-420	PIPSPHPV <mark>SQKIS</mark> KI
451-465	E NPPLINHL E HLKPL
457-471	NHLEHLKPLQPQLYD
487-501	GIPNQLNQDKPALLR
496-510	KPALLRHCKVRQPPA
502-516	HCKVRQPPAYKKGNP
511-525	YKKGNP H TRN <mark>SIKPS</mark>
517-531	HTRN <mark>SIKPS</mark> SHNGPS
547-561	QNEEYPIRP <mark>STLNS</mark> R
571-585	PHDFVF <mark>SPHNS</mark> GRPM
592-606	PPLPSYCSTNVCRCC
601-615	NVCRCCQHHSHIQYS
607-621	QHHSHIQY <mark>SPLNS</mark> WQ
631-645	DVQSEA <mark>LQKHS</mark> LFHP
652-666	YCNAFCSSSSPIALR

* Colored residues (His, Cys, Glu, Asp) are common residues for binding Zn²⁺ ions.

** The motif that was detected using the Block Maker alignment tool ¹ is colored yellow.



Figure S1: Analytical SEC of HLT STIL IDR: the protein exists as a mixture of monomer and high order oligomer.



Figure S2: STIL is composed of a high portion of Cys and His residues. Shown is the amino acid composition of several Zn^{2+} and non- Zn^{2+} binding proteins, as was calculated by the Bioinformatics Resource Portal ProtParam tool ².



Figure S3: the presence of ZnCl₂ in the medium improved the expression of HLT STIL NTD. Western blot analysis of supernatant and pellet fractions from bacterial expression of HLT STIL NTD with or without addition of ZnCl₂ to the medium.



Figure S4: The presence of $ZnCl_2$ does not affect protease digestion of OvAlbumin. Shown is SDS-PAGE gel of OvAlbumin with and without $ZnCl_2$ at several concentrations of Chymotrypsin (A), Subtilisin (B) and Proteinase K (C).



Figure S5: The presence of Zn^{2+} affects the structure of STIL IDR and NTD. A) Tryptophan fluorescence spectra of apo-STIL IDR (monomer - red) and holo-STIL IDR (multimer – black). B) Tryptophan fluorescence spectra of holo-STIL NTD (without EDTA addition – black) and apo-STIL NTD (with EDTA – red).



Figure S6: Near UV CD studies show that the structure of STIL NTD changes in presence of Zn^{2+} . Near UV CD spectra of Zn^{2+} pre-bound STIL NTD (black) and without Zn^{2+} , in the presence of EDTA (red).



Figure S7: Oligomerization of the STIL IDR: The STIL IDR peptides that mediate its oligomerization were revealed by peptide array screening and are colored green on the STIL disordered region.

```
<sup>370</sup>
ASKNFSIKRSSQKLSSGKMPIHDHDSGVEDEDFSPRPIPSPHPVSQKISKIQPSVPEL
SIVLDGNFIESNPLPTPLEMVNNENPPLINHLEHLKPLQPQLYDEKHSPEVEAGE
PSLRGIPNQLNQDKPALLRHCKVRQPPAYKKGNPHTRNSIKPSSHNGPSHDIFEK
LQTVSAGNVQNEEYPIRPSTLNSRQSSLAPQSQPHDFVFSPHNSGRPMELQIPTP
PLPSYCSTNVCRCCQHHSHIQYSPLNSWQGANTVGSIQDVQSEALQKHSLFHP
SGCPALYCNAFCSSSSPIALRPQGDMGSCSPHSNIEPSPVARPPSHMDLCNPQPC
```

Figure S8: STIL oligomerization motifs on IDR sequence. The oligomerization motif SxKxS/SxHxS/SxLxS - colored orange and the Zn binding residues found in the oligomerization sites identified by peptide array screening: Cys residues - colored green and His residues - colored pink.



Figure S9: Testing the binding of STIL NTD and HLT to arrays of peptides derived from STIL and CHFR: Screening for binding of HLT STIL NTD to an array of peptides derived from STIL NTD derived peptides in the presence of EDTA (A) or ZnCl₂ (B), and to an array of CHFR derived peptides in the presence of EDTA (C) or ZnCl₂ (D). HLT was screened for binding CHFR derived peptide array (E) and STIL derived peptide array (F). Each black spot indicates binding between the protein and the corresponding peptide.

H H H H H H S G A F E F K L P D I G E G I H E G E I V K W F V K P G D E V N E D D V L C E

V Q N D K A V V E I P S P V K G K V L E I L V P E G T V A T V G Q T L I T L D A P G Y E N M

TTGSDTGENLYFQG

А

В С Time (min) 15 30 45 60 1111411111111111111 0 0.0-Molar elipticity (deg cm²dmol⁻¹) bcal/sec -1x104 10 -2x104 KCal/Mole of EDTA 5 -3x10⁴ 0. 220 200 210 230 240 250 260 -5 λ(nm) ò ź 3 5 1 4 Molar Ratio EDTA/HLT

Figure S10: The HLT tag. (A) Primary sequence of HLT tag, composed of 6 His residues (pink), a Lipodomain (blue) and a Tev cleavage site (red). (B) CD spectrum of HLT tag. (C) ITC control - titration of EDTA into a HLT.

References

1. S. Henikoff, S. Pietrokovski, and J. G. Henikoff, *Nucleic Acids Res.*, 1998, 26, 309–312.

2. E. Gasteiger, A. Gattiker, C. Hoogland, I. Ivanyi, R. D. Appel, and A. Bairoch, *Nucleic Acids Res.*, 2003, **31**, 3784–3788.